"My years at InterWest have taught me that combining outstanding science with outstanding management is a formula for success—and that the greatest contribution I can make is to help life science entrepreneurs transform their ideas into profitable businesses with lasting value."
Arnie's Latest Buzz
Arnie has been a full-time member of InterWest's healthcare team since 1994. He is a board member of Applied Genetic Technologies Corporation (AGTC), Arcion, Centrexion, Drais Pharmaceuticals, Dynavax Technologies (DVAX), Integrated Diagnostics, PMV Pharma, RadioRX, and TESARO (TSRO).
As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Arnie brings a deep understanding of medical research to finding and investing in successful healthcare companies.
Prior to joining InterWest, Arnie was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs.
Arnie received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.
Sample of Prior Investments
AkaRx (Acquired by Eisai Pharamaceuticals in 2009), Amplimmune (Acquired by Astrazeneca in 2013), Aspreva Pharmaceuticals (IPO 2006, ASPV), Corixa (IPO 1997, CRXA), Coulter Pharmaceuticals (Acquired by Corixa in 2000), Cubist (IPO 1996, CBST), Myogen (IPO 2003), Salmedix (Acquired by Cephalon in 2005), Signal Pharmaceuticals (Acquired by Celgene in 2000)
I came to InterWest after leading a large research organization at Lederle Laboratories. It's one thing to understand the science and its potential, but quite a different challenge to turn that science into a profitable company that meets real market and health care needs. Through my years at InterWest, I have found that my greatest challenge and greatest achievement is to marry outstanding science to outstanding management in order to build a durable, successful company.